<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7779062</article-id>
    <article-id pub-id-type="pmid">33125077</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkaa924</article-id>
    <article-id pub-id-type="publisher-id">gkaa924</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>MASI: microbiota—active substance interactions database</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Zeng</surname>
          <given-names>Xian</given-names>
        </name>
        <aff><institution>Department of Biological Medicines &amp; Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy</institution>, Shanghai 201203, <country country="TW">P. R. China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yang</surname>
          <given-names>Xue</given-names>
        </name>
        <aff><institution>Department of Biological Medicines &amp; Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy</institution>, Shanghai 201203, <country country="TW">P. R. China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Fan</surname>
          <given-names>Jiajun</given-names>
        </name>
        <aff><institution>Department of Biological Medicines &amp; Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy</institution>, Shanghai 201203, <country country="TW">P. R. China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Tan</surname>
          <given-names>Ying</given-names>
        </name>
        <aff><institution>The State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Biology, Tsinghua University Shenzhen Graduate School, Shenzhen Technology and Engineering Laboratory for Personalized Cancer Diagnostics and Therapeutics, Shenzhen Kivita Innovative Drug Discovery Institute</institution>, Guangdong, <country country="TW">P. R. China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ju</surname>
          <given-names>Lingyi</given-names>
        </name>
        <aff><institution>Department of Biological Medicines &amp; Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy</institution>, Shanghai 201203, <country country="TW">P. R. China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Shen</surname>
          <given-names>Wanxiang</given-names>
        </name>
        <aff><institution>Bioinformatics and Drug Design group, Department of Pharmacy, National University of Singapore</institution>, Singapore 117543, <country country="SG">Singapore</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Yali</given-names>
        </name>
        <aff><institution>Bioinformatics and Drug Design group, Department of Pharmacy, National University of Singapore</institution>, Singapore 117543, <country country="SG">Singapore</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Xinghao</given-names>
        </name>
        <aff><institution>The State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Biology, Tsinghua University Shenzhen Graduate School, Shenzhen Technology and Engineering Laboratory for Personalized Cancer Diagnostics and Therapeutics, Shenzhen Kivita Innovative Drug Discovery Institute</institution>, Guangdong, <country country="TW">P. R. China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Weiping</given-names>
        </name>
        <!--<email>iaochen@163.com</email>-->
        <aff><institution>Key Lab of Agricultural Products Processing and Quality Control of Nanchang City, Jiangxi Agricultural University</institution>, Nanchang, 330045, <country country="TW">P. R. China</country></aff>
        <xref ref-type="corresp" rid="COR3"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ju</surname>
          <given-names>Dianwen</given-names>
        </name>
        <!--<email>dianwenju@fudan.edu.cn</email>-->
        <aff><institution>Department of Biological Medicines &amp; Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy</institution>, Shanghai 201203, <country country="TW">P. R. China</country></aff>
        <xref ref-type="corresp" rid="COR2"/>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5473-8022</contrib-id>
        <name>
          <surname>Chen</surname>
          <given-names>Yu Zong</given-names>
        </name>
        <!--<email>phacyz@nus.edu.sg</email>-->
        <aff><institution>Bioinformatics and Drug Design group, Department of Pharmacy, National University of Singapore</institution>, Singapore 117543, <country country="SG">Singapore</country></aff>
        <xref ref-type="corresp" rid="COR1"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +65 6516 6877; Fax: +65 6774 6756; Email: <email>phacyz@nus.edu.sg</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Dianwen Ju. Tel: +86 51980037; Fax: +86 51980037; Email: <email>dianwenju@fudan.edu.cn</email></corresp>
      <corresp id="COR3">Correspondence may also be addressed to Weiping Chen. Tel: +86 791 8381 3420; Fax: +86 791 8381 3655; Email: <email>iaochen@163.com</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <day>08</day>
      <month>1</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2020-10-30">
      <day>30</day>
      <month>10</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>30</day>
      <month>10</month>
      <year>2020</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
    <volume>49</volume>
    <issue>D1</issue>
    <fpage>D776</fpage>
    <lpage>D782</lpage>
    <history>
      <date date-type="accepted">
        <day>07</day>
        <month>10</month>
        <year>2020</year>
      </date>
      <date date-type="rev-recd">
        <day>28</day>
        <month>9</month>
        <year>2020</year>
      </date>
      <date date-type="received">
        <day>15</day>
        <month>8</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2021</copyright-year>
      <license license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkaa924.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Xenobiotic and host active substances interact with gut microbiota to influence human health and therapeutics. Dietary, pharmaceutical, herbal and environmental substances are modified by microbiota with altered bioavailabilities, bioactivities and toxic effects. Xenobiotics also affect microbiota with health implications. Knowledge of these microbiota and active substance interactions is important for understanding microbiota-regulated functions and therapeutics. Established microbiota databases provide useful information about the microbiota-disease associations, diet and drug interventions, and microbiota modulation of drugs. However, there is insufficient information on the active substances modified by microbiota and the abundance of gut bacteria in humans. Only ∼7% drugs are covered by the established databases. To complement these databases, we developed MASI, Microbiota—Active Substance Interactions database, for providing the information about the microbiota alteration of various substances, substance alteration of microbiota, and the abundance of gut bacteria in humans. These include 1,051 pharmaceutical, 103 dietary, 119 herbal, 46 probiotic, 142 environmental substances interacting with 806 microbiota species linked to 56 diseases and 784 microbiota–disease associations. MASI covers 11 215 bacteria-pharmaceutical, 914 bacteria-herbal, 309 bacteria-dietary, 753 bacteria-environmental substance interactions and the abundance profiles of 259 bacteria species in 3465 patients and 5334 healthy individuals. MASI is freely accessible at <ext-link ext-link-type="uri" xlink:href="http://www.aiddlab.com/MASI">http://www.aiddlab.com/MASI</ext-link>.</p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Shanghai Sailing Program</institution>
          </institution-wrap>
        </funding-source>
        <award-id>20YF1402700</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>32000479</award-id>
        <award-id>21778042</award-id>
        <award-id>81773620</award-id>
        <award-id>81573332</award-id>
        <award-id>81973512</award-id>
        <award-id>91856126</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Shanghai Science and Technology Funds</institution>
          </institution-wrap>
        </funding-source>
        <award-id>19DZ2251400</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Key Research and Development Program of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100012166</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2019YFA0905900</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Shenzhen Science and Technology Innovation Commission</institution>
            <institution-id institution-id-type="DOI">10.13039/501100010877</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2017B030314083</award-id>
        <award-id>JCYJ20170413113448742</award-id>
        <award-id>JCYJ20170816170342439</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Shenzhen Development and Reform Committee</institution>
          </institution-wrap>
        </funding-source>
        <award-id>20151961</award-id>
        <award-id>2019156</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Shenzhen Bay Laboratory</institution>
          </institution-wrap>
        </funding-source>
        <award-id>201901</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Singapore Academic Research Fund</institution>
          </institution-wrap>
        </funding-source>
        <award-id>R-148-000-273-114</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="7"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>INTRODUCTION</title>
    <p>The interactions of xenobiotic and host active substances with gut microbiota play key roles in human health, diseases and physiological responsiveness to various cues and treatments (<xref rid="B1" ref-type="bibr">1–3</xref>). Broad variety of xenobiotics such as dietary components (<xref rid="B4" ref-type="bibr">4</xref>), pharmaceuticals (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>), herbal products (<xref rid="B7" ref-type="bibr">7</xref>) and environmental chemicals (<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>) are modified by microbiota with altered bioavailabilities, bioactivities and toxic effects in the host. Some of these xenobiotics can also alter microbiota to affect their functions and communications with the host (<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B10" ref-type="bibr">10</xref>). Probiotics have been used for altering the composition of the gut microbiome and introducing beneficial effects to gut microbial communities (<xref rid="B11" ref-type="bibr">11</xref>). The comprehensive knowledge of the interaction of microbiota with the diverse active substances is important for understanding microbiota function and for developing improved therapeutics (<xref rid="B12" ref-type="bibr">12–15</xref>).</p>
    <p>Several microbiota databases have been developed for facilitating the research of the microbiota and its interactions with active substances. PharmacoMicrobiomic gives the information of microbiota regulation of drugs (covers 24 gut bacteria and 106 drugs) (<xref rid="B16" ref-type="bibr">16</xref>). Disbiome presents 10 684 microbiota–disease associations in a standardized way (<xref rid="B17" ref-type="bibr">17</xref>). Virtual Metabolic Human database (VMH) contains 17,730 unique reactions of microbiome metabolism with nutrition and diseases (<xref rid="B18" ref-type="bibr">18</xref>). gutMDisorder provides 2263/930 associations between 579/273 gut bacteria and 123/33 disorders or 77/151 interventions in human/mouse (<xref rid="B19" ref-type="bibr">19</xref>). These databases provide useful information about the microbiota-disease associations, diet and drug intervention of microbiota, and microbiota modulation of drugs. However, there is insufficient or lack of information about microbiota modification of drugs, dietary components, herbal products, and environmental chemicals. Only 152 of the &gt; 2000 approved drugs are covered by these databases. Moreover, in these databases, no data is provided for the relative abundance of microbial species in human microbiota samples.</p>
    <p>Therefore, expanded resources are needed for the information of more variety of microbiota and active substance interactions, and the relative abundance data of microbial species. To complement established databases for the additional information, we developed a new database MASI, Microbiota—Active Substance Interactions, to provide the information of microbiota alteration of active substances and active substance alteration of microbiota. The active substances include comprehensive sets of therapeutic drugs, diets/dietary components, herbal substances, probiotic products, and environmental chemicals modulated by the microbiota species or involved in the regulation of the microbiota species. Convenient search facilities were set up for keyword search and for browsing by individual classes of drugs, bacteria-active substance interactions (drug, diet, herbal substance, probiotics, environmental chemical) and bacteria–disease associations.</p>
  </sec>
  <sec id="SEC2">
    <title>DATA COLLECTION AND PROCESSING</title>
    <p>The information of microbiota alteration of active substances and active substance alteration of microbiota were searched from the literature database PubMed (<xref rid="B20" ref-type="bibr">20</xref>), by using the combinations of keywords ‘microbiota’, ‘microbiome’, ‘microbe’, ‘bacteria’, ‘gut’, ‘intestinal’, ‘xenobiotics’, ‘chemical’, ‘metabolite’, ‘metabolism’, ‘biotransformation’, ‘modulating’, ‘modulation’, ‘regulating’, ‘regulation’, ‘restoring’, ‘restoration’, ‘drug’, ‘therapeutic’, ‘food’, ‘dietary’, ‘nutrient’, ‘nutraceutical’, ‘probiotics’, ‘probiotic’, ‘prebiotics’, ‘herb’, ‘herbal’, ‘medicine’, ‘extract’, ‘environmental’ and ‘environment’. Only the experimentally determined interactions, modulations, or regulations were included in MASI. The literature-reported interaction records were manually extracted from the individual publications. The experimental details (e.g. experimental condition, chemical exposure dose and duration, effects on the host) of bacteria and active substance interactions reported in original publications were also collected when available. These interaction records were categorized into two classes, the bacteria and active substance interactions, and the bacteria and dietary substance interactions.</p>
    <p>For the identified bacteria species, their taxonomic information down to genus level was extracted from the NCBI taxonomy database (<xref rid="B21" ref-type="bibr">21</xref>). The active substances include drugs, herbs, traditional medicines, environmental chemicals/pollutants and other bioactive compounds. The bacteria and active substance interactions are further divided into the subclasses of bacteria alteration of active substances and active substance alteration of bacteria. The bacteria and dietary substance interactions are currently of a single type, i.e., dietary substance alteration of bacteria. In order for convenient access of the bacteria–disease associations relevant to the collected bacteria and active substance interactions, we further searched PubMed for the relevant bacteria-disease associations using the name of each collected bacteria and the keywords ‘disease’, ‘disorder’, ‘syndrome’, ‘cancer’, ‘leukemia’, ‘infection’, ‘inflammation’, ‘inflammatory’, ‘allergy’, ‘asthma’, ‘arthritis’, ‘diabetes’, ‘obesity’, ‘fibrosis’, ‘cirrhosis’, ‘Parkinson's’, ‘epilepsy’, ‘sepsis’, ‘colitis’, ‘fatigue’, ‘constipation’, ‘enterocolitis’ and ‘eczema’. The searched literatures were manually evaluated for finding the experimentally indicated bacteria-disease relationship, i.e. the increase/decrease of the relative abundance of the bacteria is associated with the disease. Moreover, probiotics were extracted from Probio database (<xref rid="B22" ref-type="bibr">22</xref>) by the bacteria species matching using the corresponding scientific name or NCBI taxonomic identifier.</p>
    <p>The SMILES strings of the chemical substances were extracted from PubChem database (<xref rid="B23" ref-type="bibr">23</xref>) by matching PubChem CID identifiers or by manual matching and inspection of the substance names with those in the PubChem records. The SMILES strings were subsequently converted to structure images using OpenBabel command line script (<xref rid="B24" ref-type="bibr">24</xref>). The Anatomical Therapeutic Chemical Classification System (ATC) codes of the drugs were from DrugBank database (<xref rid="B25" ref-type="bibr">25</xref>) by matching DrugBank identifiers or PubChem CID identifiers with those in the DrugBank records. Cytoscape software (<xref rid="B26" ref-type="bibr">26</xref>) was used for generating the bacteria-substance-disease association networks, which are provided in the respective MASI webpage for visualization.</p>
    <p>The pre-processed gut bacteria abundance level in the patients and healthy individuals are from the curatedMetagenomicData resource (<xref rid="B27" ref-type="bibr">27</xref>). The curatedMetagenomicData processes metagenomic data with a unified analysis pipeline to calculate the relative abundance from raw sequencing data. In the relative abundance matrix, the sum of microbial abundance of an individual microbiota sample was standardized to 1 at each taxonomic level (e.g. species, genus, family). Relative abundance of each bacteria species was log<sub>10</sub> transformed (resulted relative abundance levels range from –7 to 0) for convenient visualization. Ridgeline plots were generated using ggplot2 R package to show relative abundance profiles of individual bacteria species across ages and geographical regions of patients, and disease conditions.</p>
  </sec>
  <sec id="SEC3">
    <title>MICROBIOTA AND ACTIVE SUBSTANCE INTERACTIONS</title>
    <p>Active substances such as drugs, dietary supplements, herbal products and probiotics have been widely used for therapeutic, nutritional and health beneficial effects. Many of these active substances affect microbiota with either beneficial or adverse effects. For example, in a study of &gt;1000 approved non-antibiotic drugs against 40 representative gut bacterial strains, there appear to be partially overlapped resistance mechanisms of antibiotics and non-antibiotic drugs, suggesting that microbial species which are multi-drug resistant to antibiotics may in some cases be more resistant to human-targeted drugs (<xref rid="B28" ref-type="bibr">28</xref>). Various strategies have been explored for improved therapeutic response in cancer treatment by the modulation of gut microbiome, which include faecal microbiota transplants, probiotics, diet, and prebiotics intervention (<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref>). The consumption of antibiotic drugs may alter the host microbiota, resulting in dysregulation of host immune homeostasis and an increased susceptibility to disease (<xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B32" ref-type="bibr">32</xref>). The antihyperlipidemic function of <italic>Coptis chinensis</italic> alkaloids partly arise from their modulation of gut microbiota and bile acid pathway to reduce triglycerides, total cholesterols, low-density lipoprotein cholesterols, lipopolysaccharides, and total bile acids, leading to the beneficial effects in the treatment of high-fat diet induced hyperlipidemia (<xref rid="B33" ref-type="bibr">33</xref>). Therefore, the information of the regulation of microbiota by active substances is important for the investigations and manipulations of gut microbiota in searching of improved therapeutics.</p>
    <p>Moreover, many drugs, dietary components, and herbal products are modified by gut microbiota with functional and therapeutic implications. For instance, the nucleoside analog drug brivudine can be converted to hepatotoxic bromovinyluracil by both mammalian and microbial enzymes, suggesting a microbiome contribution to brivudine pharmacokinetics and toxicity (<xref rid="B13" ref-type="bibr">13</xref>). Studies of 271 clinical drugs have found 176 drugs metabolized by at least 1 of the 76 tested human gut bacterial strains, some of which are expected to influence intestinal and systemic drug and drug-metabolite exposure (<xref rid="B5" ref-type="bibr">5</xref>). Dietary fibers are metabolized by gut microbiota into short-chain fatty acids, which mediate gut-brain communications with beneficial effects on cognitive, immune and endocrine functions (<xref rid="B34" ref-type="bibr">34</xref>). Ellagitannin-rich herbs are popular remedies in the treatment of various inflammatory diseases, and ellagitannins in these herbs are metabolized by gut microbiota into anti-inflammatory urolithins partly responsible for their observed beneficial effects (<xref rid="B35" ref-type="bibr">35</xref>). Hence, the knowledge of the modulation of active substances by microbiota is highly useful for the full understanding and exploration of the effects of drugs, foods and herbal products on human health.</p>
  </sec>
  <sec id="SEC4">
    <title>MICROBIOTA INTERACTIONS WITH ENVIROMENTAL CHEMICALS</title>
    <p>Environmental chemicals strongly influence microbiota communities with implications to human health (<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B36" ref-type="bibr">36</xref>). In a study of the impact of confined swine farm environments on gut microbiome and resistome of veterinary students, it has been found that farm exposure shapes the gut microbiome of these students, with enrichment of potentially pathogenic taxa and antimicrobial resistance genes (<xref rid="B37" ref-type="bibr">37</xref>). The potentially adverse effects include increased risk of adenocarcinoma in the lower esophagus and decreased modulation of immunologic, endocrine, and physiologic functions in the stomach. The potentially beneficial effects include decreased risks of ulcers, gastric adenocarcinoma and lymphoma. Bisphenol A (BPA), a plastic monomer of high-volume industrial chemical with endocrine-disrupting toxicity, has been found to alter a variety of gut microbiota species (<xref rid="B26" ref-type="bibr">26</xref>). For instance, BPA exposure has led to increased <italic>Prevotellaceae</italic> in the gut microbiome of male mice, which may affect the mucosal barrier function (<xref rid="B38" ref-type="bibr">38</xref>), BPA exposure has also led to upregulated <italic>Akkermansia</italic> and <italic>Methanobrevibacter</italic> in the gut microbiome of males, which is of concern of cancer risks because <italic>Akkermansia</italic> is involved in butyrate production and is frequently elevated in human cancers (<xref rid="B39" ref-type="bibr">39</xref>,<xref rid="B40" ref-type="bibr">40</xref>). A third study has found that exposure to trace-level dust from a high biodiversity soil can change gut microbiota in comparison to dust from low biodiversity soil or no soil, which indicates that biodiverse soils may be an important source of butyrate-producing bacteria for resupplying the mammalian gut microbiome with potential gut and mental health benefits (<xref rid="B41" ref-type="bibr">41</xref>). Thus, information of the interactions between microbiota and environment is needed for a more complete investigation and understanding of the microbiota functions and interventions.</p>
  </sec>
  <sec id="SEC5">
    <title>GUT BACTERIA ABUNDANCE AND HUMAN HEALTH</title>
    <p>The alterations of relative abundance of gut bacteria are closely associated with human health and diseases. For instance, differences in the composition and function of gut microbial communities contribute to individual variations in cytokine responses to microbial stimulations in healthy individuals (<xref rid="B42" ref-type="bibr">42</xref>). Moreover, in a recent investigation of the contributions of impaired gut microbial community development to childhood undernutrition, a microbiota-directed complementary food has been identified that changes the abundances of targeted microbiota bacteria, resulting in enhanced growth, bone formation, neurodevelopment, and immune function in children with moderate acute malnutrition (<xref rid="B43" ref-type="bibr">43</xref>). Treatment of mice with an antibiotic cocktail results in the perturbation of the abundance of specific members of the microbiota communities, and the perturbation impairs the response of subcutaneous tumors to CpG-oligonucleotide immunotherapy and platinum chemotherapy (<xref rid="B44" ref-type="bibr">44</xref>). Therefore, gut bacteria abundance information is essential for the investigation of the microbiota and its interaction with active substance.</p>
  </sec>
  <sec id="SEC6">
    <title>DATABASE CONTENTS, STRUCTURE, AND ACCESS</title>
    <p>MASI is freely accessible at <ext-link ext-link-type="uri" xlink:href="http://www.aiddlab.com/MASI">http://www.aiddlab.com/MASI</ext-link> (homepage in Figure <xref ref-type="fig" rid="F1">1</xref>). As shown in Table <xref rid="tbl1" ref-type="table">1</xref>, it currently covers 11 215 bacteria-drug, 914 bacteria-herbal substance, 309 bacteria-dietary component, 753 bacteria-environmental chemical interactions. These interactions involve 980 approved drugs, 103 dietary components, 119 herbal substances, 46 probiotic products and 142 environmental chemicals interacting with 806 bacteria species and in 56 human diseases. The relative abundance profiles of 259 bacteria species in 3465 patients and 5334 healthy individuals are provided. Among four substance categories, microbiota-therapeutic substances interactions account for the majority of the total 11 752 interaction records in MASI (Table <xref rid="tbl2" ref-type="table">2</xref>). MASI can be searched by keywords and by browsing the substances (drug, dietary, herbal substance, probiotics, environmental), interactions (microbiota alteration of substance, substance alteration of microbiota), and bacteria-disease associations. In the MASI browse page, the interactions can be filtered by selecting the respective fields of bacteria and active substance interactions, bacteria and dietary substance interactions, bacteria and environmental chemical interactions, and bacteria-disease associations.</p>
    <fig id="F1" orientation="portrait" position="float">
      <label>Figure 1.</label>
      <caption>
        <p>The homepage of MASI web interface. The webpage allows users to search microbiota species, therapeutic substances, or disease by keywords. All entries of MASI can be browsed or downloaded by clicking the ‘Browse’ or ‘Download’ buttons in the top menu.</p>
      </caption>
      <graphic xlink:href="gkaa924fig1"/>
    </fig>
    <table-wrap id="tbl1" orientation="portrait" position="float">
      <label>Table 1.</label>
      <caption>
        <p>Overall statistics of MASI database</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="1" colspan="1"/>
            <th rowspan="1" colspan="1">No. of entries</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="1" colspan="1">Unique bacteria species</td>
            <td rowspan="1" colspan="1">806</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Unique substances</td>
            <td rowspan="1" colspan="1">1350</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Unique diseases</td>
            <td rowspan="1" colspan="1">56</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Unique bacteria species with abundance profile available</td>
            <td rowspan="1" colspan="1">259</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Unique bacteria–substance interaction pairs</td>
            <td rowspan="1" colspan="1">11 752</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Unique interaction pairs: bacteria alter substances</td>
            <td rowspan="1" colspan="1">4001</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Unique interaction pairs: substances alter bacteria abundance</td>
            <td rowspan="1" colspan="1">7770</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Unique bacteria–disease associations</td>
            <td rowspan="1" colspan="1">784</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap id="tbl2" orientation="portrait" position="float">
      <label>Table 2.</label>
      <caption>
        <p>Number of entries of microbiota - active substances interactions in each category/subcategory of substances. One substance may belong to multiple subcategories</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="1" colspan="1">Substance category—subcategory</th>
            <th rowspan="1" colspan="1">No. of substances</th>
            <th rowspan="1" colspan="1">No. of interactions (bacteria alter substances)</th>
            <th rowspan="1" colspan="1">No. of interactions (substances alter bacteria abundance)</th>
            <th rowspan="1" colspan="1">Total no. of interactions</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="1" colspan="1">Therapeutic substance (all)</td>
            <td rowspan="1" colspan="1">1074</td>
            <td rowspan="1" colspan="1">4134</td>
            <td rowspan="1" colspan="1">7081</td>
            <td rowspan="1" colspan="1">11 215</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Therapeutic substance—approved drug (human)</td>
            <td rowspan="1" colspan="1">980</td>
            <td rowspan="1" colspan="1">3947</td>
            <td rowspan="1" colspan="1">6544</td>
            <td rowspan="1" colspan="1">10 491</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Therapeutic substance—approved drug (veterinary medicine)</td>
            <td rowspan="1" colspan="1">16</td>
            <td rowspan="1" colspan="1">0</td>
            <td rowspan="1" colspan="1">362</td>
            <td rowspan="1" colspan="1">362</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Therapeutic substance—drug class</td>
            <td rowspan="1" colspan="1">41</td>
            <td rowspan="1" colspan="1">51</td>
            <td rowspan="1" colspan="1">139</td>
            <td rowspan="1" colspan="1">190</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Therapeutic substance—investigational drug</td>
            <td rowspan="1" colspan="1">30</td>
            <td rowspan="1" colspan="1">118</td>
            <td rowspan="1" colspan="1">47</td>
            <td rowspan="1" colspan="1">165</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Dietary substance (all)</td>
            <td rowspan="1" colspan="1">103</td>
            <td rowspan="1" colspan="1">42</td>
            <td rowspan="1" colspan="1">267</td>
            <td rowspan="1" colspan="1">309</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Dietary substance—artificial sweeteners</td>
            <td rowspan="1" colspan="1">5</td>
            <td rowspan="1" colspan="1">6</td>
            <td rowspan="1" colspan="1">14</td>
            <td rowspan="1" colspan="1">20</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Dietary substance—dietary Compounds</td>
            <td rowspan="1" colspan="1">72</td>
            <td rowspan="1" colspan="1">46</td>
            <td rowspan="1" colspan="1">138</td>
            <td rowspan="1" colspan="1">184</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Dietary substance—drinks</td>
            <td rowspan="1" colspan="1">20</td>
            <td rowspan="1" colspan="1">1</td>
            <td rowspan="1" colspan="1">80</td>
            <td rowspan="1" colspan="1">81</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Dietary substance—foods</td>
            <td rowspan="1" colspan="1">13</td>
            <td rowspan="1" colspan="1">0</td>
            <td rowspan="1" colspan="1">34</td>
            <td rowspan="1" colspan="1">34</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Herbal substance (all)</td>
            <td rowspan="1" colspan="1">119</td>
            <td rowspan="1" colspan="1">367</td>
            <td rowspan="1" colspan="1">547</td>
            <td rowspan="1" colspan="1">914</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Herbal substance—medicinal herb</td>
            <td rowspan="1" colspan="1">24</td>
            <td rowspan="1" colspan="1">2</td>
            <td rowspan="1" colspan="1">115</td>
            <td rowspan="1" colspan="1">117</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Herbal substance—medicinal herbal compounds</td>
            <td rowspan="1" colspan="1">87</td>
            <td rowspan="1" colspan="1">364</td>
            <td rowspan="1" colspan="1">405</td>
            <td rowspan="1" colspan="1">769</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Herbal substance—TCM formula</td>
            <td rowspan="1" colspan="1">5</td>
            <td rowspan="1" colspan="1">0</td>
            <td rowspan="1" colspan="1">24</td>
            <td rowspan="1" colspan="1">24</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Environmental substance (all)</td>
            <td rowspan="1" colspan="1">142</td>
            <td rowspan="1" colspan="1">37</td>
            <td rowspan="1" colspan="1">716</td>
            <td rowspan="1" colspan="1">753</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Environmental substance—heavy metals</td>
            <td rowspan="1" colspan="1">10</td>
            <td rowspan="1" colspan="1">4</td>
            <td rowspan="1" colspan="1">158</td>
            <td rowspan="1" colspan="1">162</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Environmental substance—persistent organic pollutants</td>
            <td rowspan="1" colspan="1">14</td>
            <td rowspan="1" colspan="1">0</td>
            <td rowspan="1" colspan="1">94</td>
            <td rowspan="1" colspan="1">94</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1">Environmental substance—pesticides</td>
            <td rowspan="1" colspan="1">26</td>
            <td rowspan="1" colspan="1">0</td>
            <td rowspan="1" colspan="1">269</td>
            <td rowspan="1" colspan="1">269</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <p>For each individual bacteria species, the interaction information was presented in five sections (Figure <xref ref-type="fig" rid="F2">2</xref>): Section-1 ‘Bacteria–Drug Interactions’ shows the detailed information of alteration effect of bacteria on the bioavailability, bioactivity or toxicity of drugs and alteration effects of drugs on bacteria abundance in human gut or proliferation in <italic>in vitro</italic> assays. Similar information was presented in Section-2 ‘Bacteria–Herbal Substance Interactions’ and Section-3 ‘Bacteria–Dietary Substance Interactions’. Section-4 shows the ‘Bacteria–Disease Associations’ to cover those bacteria that have bacteria–active substance interaction records in MASI. Section-5 provides relative abundance profile of the bacteria species in healthy population and various disease conditions. For each individual substance, a substance page provides ‘Bacteria–Drug Interactions’ and ‘Probiotics-Substance Interactions’ records relevant to this substance.</p>
    <fig id="F2" orientation="portrait" position="float">
      <label>Figure 2.</label>
      <caption>
        <p>An example webpage of microbiota species. The top section provides taxonomic classification of the bacteria species. Microbiota–active substance interaction records are grouped into different categories and presented in individual tables. Users can click the fingerprint-like button in the ‘Reference (PubMed ID)’ column to see detailed information of each reference. All records shown in table can be downloaded via ‘CSV’, ‘Excel’ and ‘PDF’ download options in the left-top of each table. Detailed interaction data of substance can be accessed by clicking substance name in each row.</p>
      </caption>
      <graphic xlink:href="gkaa924fig2"/>
    </fig>
    <p>As shown in Figure <xref ref-type="fig" rid="F3">3</xref>, active substances in MASI interaction records tend to concentrate on a few regions on the phylogenetic tree of microbiota species. The number of substances interacting with individual bacteria species ranges from 1 to 203. The top five bacteria species <italic>Roseburia intestinalis, Eubacterium rectale, Bacteroides vulgatus, Clostridium perfringens</italic> and <italic>Coprococcus comes</italic> have 203, 198, 194, 182 and 180 known interactive substances, respectively, while about 83% of bacteria species in MASI have &lt;10 known interactive substances. From higher taxonomic level perspectives, bacteria-active substance interactions mainly distributed in <italic>Bacteroidales</italic> order, <italic>Lachnospiraceae</italic> family and <italic>Escherichia</italic> genus.</p>
    <fig id="F3" orientation="portrait" position="float">
      <label>Figure 3.</label>
      <caption>
        <p>Active substance distribution in the phylogenetic tree of human microbiota species. 532 bacteria species with NCBI Taxonomic Identifier available were included in this tree. The number of substances of individual bacteria species ranges from 1 to 203. Phylogenetic tree of microbiota species was generated based on Taxonomy Identifiers using phyloT webserver and annotated and visualized by iTOL software (<xref rid="B50" ref-type="bibr">50</xref>).</p>
      </caption>
      <graphic xlink:href="gkaa924fig3"/>
    </fig>
    <p>MASI was developed with MySQL backend and PHP server software. Its web-interfaces were built with HTML5, PHP, and JavaScript, and were designed to enable the convenient access of its entries by browsing or searching microbiota species, substances (e.g. approved drugs, dietary compounds, medicinal herbs, antibiotics), and diseases. While applicable, the microbiota species entries are cross-linked to NCBI Taxonomy database (<xref rid="B21" ref-type="bibr">21</xref>), chemical substances entries are crosslinked to ChEMBL (<xref rid="B45" ref-type="bibr">45</xref>), DrugBank (<xref rid="B25" ref-type="bibr">25</xref>), Therapeutic Target Database (TTD) (<xref rid="B46" ref-type="bibr">46</xref>), PubChem (<xref rid="B23" ref-type="bibr">23</xref>) and Natural Product Activity and Species Source database (NPASS) (<xref rid="B47" ref-type="bibr">47</xref>). The references for each microbiota-active substance interaction are listed with PubMed identifiers or DOIs below each entry for conveniently tracing back to original studies. All interaction entries can be freely and conveniently downloaded using the download functions provided in each individual bacteria/substance webpage. Alternatively, users can download whole datasets of MASI from the ‘Download’ webpage with a format of either plain text or Excel tables.</p>
  </sec>
  <sec id="SEC7">
    <title>PERSPECTIVES</title>
    <p>Microbiota plays vital roles in human health (<xref rid="B1" ref-type="bibr">1</xref>) and its malfunction and dysregulation may lead to health problems (<xref rid="B37" ref-type="bibr">37</xref>). The state of microbiota and its broad effects is significantly influenced by the interactions of microbiota with various active substances (<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B35" ref-type="bibr">35</xref>) and environmental chemicals (<xref rid="B41" ref-type="bibr">41</xref>). MASI as well as other established microbiota databases (<xref rid="B16" ref-type="bibr">16–19</xref>) collectively serve as useful resources for the relevant information and for facilitating the research and exploration of microbiota in the promotion of human health. There have been new advances in the large-scale genomic studies of the functional microbiome of &gt;6000 gut bacteria (<xref rid="B48" ref-type="bibr">48</xref>), longitudinal analysis of the ecological states in gut microbiome (<xref rid="B49" ref-type="bibr">49</xref>), the mapping of the human microbiome drug metabolizing genes (<xref rid="B5" ref-type="bibr">5</xref>), and the design of microbiota-targeted foods for the treatment of diseases promoted by the malfunctional or dysregulated microbiota (<xref rid="B43" ref-type="bibr">43</xref>). The rich information generated from these and future investigations can be incorporated into MASI and other established microbiota databases for better serving the microbiota research and exploration efforts. We aim to regularly update the newly-emerging information into MASI.</p>
  </sec>
</body>
<back>
  <sec id="SEC8">
    <title>FUNDING</title>
    <p>Shanghai Sailing Program [20YF1402700]; National Natural Science Foundation of China [32000479, 21778042, 81773620, 81573332, 81973512, 91856126]; Shanghai Science and Technology Funds [19DZ2251400]; National Key R&amp;D Program of China [2019YFA0905900]; Shenzhen Science, Technology and Innovation Commission Grants [2017B030314083, JCYJ20170413113448742, JCYJ20170816170342439]; Shenzhen Development and Reform Committee [20151961, 2019156]; Shenzhen Bay Laboratory [NO.201901]; Singapore Academic Research Fund [R-148-000-273-114]. Funding for open access charge: Shanghai Sailing Program [20YF1402700].</p>
    <p><italic>Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gould</surname><given-names>A.L.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Lamberti</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>E.W.</given-names></name>, <name name-style="western"><surname>Obadia</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Korasidis</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Gavryushkin</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Carlson</surname><given-names>J.M.</given-names></name>, <name name-style="western"><surname>Beerenwinkel</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Ludington</surname><given-names>W.B.</given-names></name></person-group><article-title>Microbiome interactions shape host fitness</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2018</year>; <volume>115</volume>:<fpage>E11951</fpage>–<lpage>E11960</lpage>.<pub-id pub-id-type="pmid">30510004</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koppel</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Maini Rekdal</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Balskus</surname><given-names>E.P.</given-names></name></person-group><article-title>Chemical transformation of xenobiotics by the human gut microbiota</article-title>. <source>Science</source>. <year>2017</year>; <volume>356</volume>:<fpage>eaag2770</fpage>.<pub-id pub-id-type="pmid">28642381</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clarke</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Sandhu</surname><given-names>K.V.</given-names></name>, <name name-style="western"><surname>Griffin</surname><given-names>B.T.</given-names></name>, <name name-style="western"><surname>Dinan</surname><given-names>T.G.</given-names></name>, <name name-style="western"><surname>Cryan</surname><given-names>J.F.</given-names></name>, <name name-style="western"><surname>Hyland</surname><given-names>N.P.</given-names></name></person-group><article-title>Gut reactions: breaking down xenobiotic-microbiome interactions</article-title>. <source>Pharmacol. Rev.</source><year>2019</year>; <volume>71</volume>:<fpage>198</fpage>–<lpage>224</lpage>.<pub-id pub-id-type="pmid">30890566</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowland</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Gibson</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Heinken</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Scott</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Swann</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Thiele</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Tuohy</surname><given-names>K.</given-names></name></person-group><article-title>Gut microbiota functions: metabolism of nutrients and other food components</article-title>. <source>Eur. J. Nutr.</source><year>2018</year>; <volume>57</volume>:<fpage>1</fpage>–<lpage>24</lpage>.</mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmermann</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zimmermann-Kogadeeva</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Wegmann</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Goodman</surname><given-names>A.L.</given-names></name></person-group><article-title>Mapping human microbiome drug metabolism by gut bacteria and their genes</article-title>. <source>Nature</source>. <year>2019</year>; <volume>570</volume>:<fpage>462</fpage>–<lpage>467</lpage>.<pub-id pub-id-type="pmid">31158845</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weersma</surname><given-names>R.K.</given-names></name>, <name name-style="western"><surname>Zhernakova</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>J.</given-names></name></person-group><article-title>Interaction between drugs and the gut microbiome</article-title>. <source>Gut</source>. <year>2020</year>; <volume>69</volume>:<fpage>1510</fpage>–<lpage>1519</lpage>.<pub-id pub-id-type="pmid">32409589</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>H.B.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>S.L.</given-names></name></person-group><article-title>Understanding the molecular mechanisms of the interplay between herbal medicines and gut microbiota</article-title>. <source>Med. Res. Rev.</source><year>2017</year>; <volume>37</volume>:<fpage>1140</fpage>–<lpage>1185</lpage>.<pub-id pub-id-type="pmid">28052344</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiu</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Warner</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Nowak</surname><given-names>R.A.</given-names></name>, <name name-style="western"><surname>Flaws</surname><given-names>J.A.</given-names></name>, <name name-style="western"><surname>Mei</surname><given-names>W.</given-names></name></person-group><article-title>The impact of environmental chemicals on the gut microbiome</article-title>. <source>Toxicol. Sci.</source><year>2020</year>; <volume>176</volume>:<fpage>253</fpage>–<lpage>284</lpage>.<pub-id pub-id-type="pmid">32392306</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tasnim</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Abulizi</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Pither</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Hart</surname><given-names>M.M.</given-names></name>, <name name-style="western"><surname>Gibson</surname><given-names>D.L.</given-names></name></person-group><article-title>Linking the gut microbial ecosystem with the environment: does gut health depend on where we live</article-title>. <source>Front Microbiol</source>. <year>2017</year>; <volume>8</volume>:<fpage>1935</fpage>.<pub-id pub-id-type="pmid">29056933</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>W.S.</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>A.W.</given-names></name>, <name name-style="western"><surname>Louis</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Parkhill</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Vermeiren</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Bosscher</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Duncan</surname><given-names>S.H.</given-names></name>, <name name-style="western"><surname>Flint</surname><given-names>H.J.</given-names></name></person-group><article-title>Modulation of the human gut microbiota by dietary fibres occurs at the species level</article-title>. <source>BMC Biol.</source><year>2016</year>; <volume>14</volume>:<fpage>3</fpage>.<pub-id pub-id-type="pmid">26754945</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hemarajata</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Versalovic</surname><given-names>J.</given-names></name></person-group><article-title>Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation</article-title>. <source>Therap Adv Gastroenterol</source>. <year>2013</year>; <volume>6</volume>:<fpage>39</fpage>–<lpage>51</lpage>.</mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicolas</surname><given-names>G.R.</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>P.V.</given-names></name></person-group><article-title>Deciphering the chemical lexicon of host-gut microbiota interactions</article-title>. <source>Trends Pharmacol. Sci.</source><year>2019</year>; <volume>40</volume>:<fpage>430</fpage>–<lpage>445</lpage>.<pub-id pub-id-type="pmid">31079848</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmermann</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zimmermann-Kogadeeva</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Wegmann</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Goodman</surname><given-names>A.L.</given-names></name></person-group><article-title>Separating host and microbiome contributions to drug pharmacokinetics and toxicity</article-title>. <source>Science</source>. <year>2019</year>; <volume>363</volume>:<fpage>eaat9931</fpage>.<pub-id pub-id-type="pmid">30733391</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doestzada</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Vila</surname><given-names>A.V.</given-names></name>, <name name-style="western"><surname>Zhernakova</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Koonen</surname><given-names>D.P.Y.</given-names></name>, <name name-style="western"><surname>Weersma</surname><given-names>R.K.</given-names></name>, <name name-style="western"><surname>Touw</surname><given-names>D.J.</given-names></name>, <name name-style="western"><surname>Kuipers</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Wijmenga</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>J.</given-names></name></person-group><article-title>Pharmacomicrobiomics: a novel route towards personalized medicine</article-title>. <source>Protein Cell</source>. <year>2018</year>; <volume>9</volume>:<fpage>432</fpage>–<lpage>445</lpage>.<pub-id pub-id-type="pmid">29705929</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colotti</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Rinaldi</surname><given-names>T.</given-names></name></person-group><article-title>The central role of gut microbiota in drug metabolism and personalized medicine</article-title>. <source>Future Med Chem</source>. <year>2020</year>; <volume>12</volume>:<fpage>1197</fpage>–<lpage>1200</lpage>.<pub-id pub-id-type="pmid">32466672</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aziz</surname><given-names>R.K.</given-names></name>, <name name-style="western"><surname>Saad</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Rizkallah</surname><given-names>M.R.</given-names></name></person-group><article-title>PharmacoMicrobiomics or how bugs modulate drugs: an educational initiative to explore the effects of human microbiome on drugs</article-title>. <source>BMC Bioinformatics</source>. <year>2011</year>; <volume>12</volume>:<fpage>A10</fpage>.</mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janssens</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Nielandt</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Bronselaer</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Debunne</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Verbeke</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Wynendaele</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Van Immerseel</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Vandewynckel</surname><given-names>Y.P.</given-names></name>, <name name-style="western"><surname>De Tre</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>De Spiegeleer</surname><given-names>B.</given-names></name></person-group><article-title>Disbiome database: linking the microbiome to disease</article-title>. <source>BMC Microbiol.</source><year>2018</year>; <volume>18</volume>:<fpage>50</fpage>.<pub-id pub-id-type="pmid">29866037</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noronha</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Modamio</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Jarosz</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Guerard</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Sompairac</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Preciat</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Danielsdottir</surname><given-names>A.D.</given-names></name>, <name name-style="western"><surname>Krecke</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Merten</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Haraldsdottir</surname><given-names>H.S.</given-names></name><etal>et al</etal>.</person-group><article-title>The Virtual Metabolic Human database: integrating human and gut microbiome metabolism with nutrition and disease</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D614</fpage>–<lpage>D624</lpage>.<pub-id pub-id-type="pmid">30371894</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Qi</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Zhuang</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>gutMDisorder: a comprehensive database for dysbiosis of the gut microbiota in disorders and interventions</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D554</fpage>–<lpage>D560</lpage>.<pub-id pub-id-type="pmid">31584099</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sayers</surname><given-names>E.W.</given-names></name>, <name name-style="western"><surname>Beck</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Brister</surname><given-names>J.R.</given-names></name>, <name name-style="western"><surname>Bolton</surname><given-names>E.E.</given-names></name>, <name name-style="western"><surname>Canese</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Comeau</surname><given-names>D.C.</given-names></name>, <name name-style="western"><surname>Funk</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Ketter</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Kimchi</surname><given-names>A.</given-names></name><etal>et al</etal>.</person-group><article-title>Database resources of the National Center for Biotechnology Information</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D9</fpage>–<lpage>D16</lpage>.<pub-id pub-id-type="pmid">31602479</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Federhen</surname><given-names>S.</given-names></name></person-group><article-title>The NCBI Taxonomy database</article-title>. <source>Nucleic Acids Res.</source><year>2012</year>; <volume>40</volume>:<fpage>D136</fpage>–<lpage>143</lpage>.<pub-id pub-id-type="pmid">22139910</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Pow</surname><given-names>S.H.</given-names></name>, <name name-style="western"><surname>Zeng</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Qin</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>He</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>Y.</given-names></name><etal>et al</etal>.</person-group><article-title>Database and bioinformatics studies of probiotics</article-title>. <source>J. Agric. Food Chem.</source><year>2017</year>; <volume>65</volume>:<fpage>7599</fpage>–<lpage>7606</lpage>.<pub-id pub-id-type="pmid">28727425</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Bryant</surname><given-names>S.H.</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Gindulyte</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Shoemaker</surname><given-names>B.A.</given-names></name>, <name name-style="western"><surname>Thiessen</surname><given-names>P.A.</given-names></name>, <name name-style="western"><surname>He</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name></person-group><article-title>PubChem BioAssay: 2017 update</article-title>. <source>Nucleic Acids Res.</source><year>2017</year>; <volume>45</volume>:<fpage>D955</fpage>–<lpage>D963</lpage>.<pub-id pub-id-type="pmid">27899599</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O’Boyle</surname><given-names>N.M.</given-names></name>, <name name-style="western"><surname>Banck</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>James</surname><given-names>C.A.</given-names></name>, <name name-style="western"><surname>Morley</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Vandermeersch</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Hutchison</surname><given-names>G.R.</given-names></name></person-group><article-title>Open Babel: an open chemical toolbox</article-title>. <source>J Cheminform</source>. <year>2011</year>; <volume>3</volume>:<fpage>33</fpage>.<pub-id pub-id-type="pmid">21982300</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wishart</surname><given-names>D.S.</given-names></name>, <name name-style="western"><surname>Feunang</surname><given-names>Y.D.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>A.C.</given-names></name>, <name name-style="western"><surname>Lo</surname><given-names>E.J.</given-names></name>, <name name-style="western"><surname>Marcu</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Grant</surname><given-names>J.R.</given-names></name>, <name name-style="western"><surname>Sajed</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Sayeeda</surname><given-names>Z.</given-names></name><etal>et al</etal>.</person-group><article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D1074</fpage>–<lpage>D1082</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shannon</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Markiel</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Ozier</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Baliga</surname><given-names>N.S.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J.T.</given-names></name>, <name name-style="western"><surname>Ramage</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Amin</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Schwikowski</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Ideker</surname><given-names>T.</given-names></name></person-group><article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title>. <source>Genome Res.</source><year>2003</year>; <volume>13</volume>:<fpage>2498</fpage>–<lpage>2504</lpage>.<pub-id pub-id-type="pmid">14597658</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasolli</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Schiffer</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Manghi</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Renson</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Obenchain</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Truong</surname><given-names>D.T.</given-names></name>, <name name-style="western"><surname>Beghini</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Malik</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Ramos</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Dowd</surname><given-names>J.B.</given-names></name><etal>et al</etal>.</person-group><article-title>Accessible, curated metagenomic data through ExperimentHub</article-title>. <source>Nat. Methods</source>. <year>2017</year>; <volume>14</volume>:<fpage>1023</fpage>–<lpage>1024</lpage>.<pub-id pub-id-type="pmid">29088129</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maier</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Pruteanu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Kuhn</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zeller</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Telzerow</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>E.E.</given-names></name>, <name name-style="western"><surname>Brochado</surname><given-names>A.R.</given-names></name>, <name name-style="western"><surname>Fernandez</surname><given-names>K.C.</given-names></name>, <name name-style="western"><surname>Dose</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Mori</surname><given-names>H.</given-names></name><etal>et al</etal>.</person-group><article-title>Extensive impact of non-antibiotic drugs on human gut bacteria</article-title>. <source>Nature</source>. <year>2018</year>; <volume>555</volume>:<fpage>623</fpage>–<lpage>628</lpage>.<pub-id pub-id-type="pmid">29555994</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McQuade</surname><given-names>J.L.</given-names></name>, <name name-style="western"><surname>Daniel</surname><given-names>C.R.</given-names></name>, <name name-style="western"><surname>Helmink</surname><given-names>B.A.</given-names></name>, <name name-style="western"><surname>Wargo</surname><given-names>J.A.</given-names></name></person-group><article-title>Modulating the microbiome to improve therapeutic response in cancer</article-title>. <source>Lancet Oncol.</source><year>2019</year>; <volume>20</volume>:<fpage>e77</fpage>–<lpage>e91</lpage>.<pub-id pub-id-type="pmid">30712808</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucafo</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Franzin</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Lagatolla</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Franca</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Bramuzzo</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Stocco</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Decorti</surname><given-names>G.</given-names></name></person-group><article-title>Emerging insights on the interaction between anticancer and immunosuppressant drugs and intestinal microbiota in pediatric patients</article-title>. <source>Clin Transl Sci</source>. <year>2020</year>; <volume>13</volume>:<fpage>238</fpage>–<lpage>259</lpage>.<pub-id pub-id-type="pmid">31675176</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmermann</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Curtis</surname><given-names>N.</given-names></name></person-group><article-title>The effect of antibiotics on the composition of the intestinal microbiota - a systematic review</article-title>. <source>J. Infect.</source><year>2019</year>; <volume>79</volume>:<fpage>471</fpage>–<lpage>489</lpage>.<pub-id pub-id-type="pmid">31629863</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willing</surname><given-names>B.P.</given-names></name>, <name name-style="western"><surname>Russell</surname><given-names>S.L.</given-names></name>, <name name-style="western"><surname>Finlay</surname><given-names>B.B.</given-names></name></person-group><article-title>Shifting the balance: antibiotic effects on host-microbiota mutualism</article-title>. <source>Nat. Rev. Microbiol.</source><year>2011</year>; <volume>9</volume>:<fpage>233</fpage>–<lpage>243</lpage>.<pub-id pub-id-type="pmid">21358670</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X.M.</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>R.X.</given-names></name></person-group><article-title>Interaction between gut microbiota and ethnomedicine constituents</article-title>. <source>Nat. Prod. Rep.</source><year>2019</year>; <volume>36</volume>:<fpage>788</fpage>–<lpage>809</lpage>.<pub-id pub-id-type="pmid">30534698</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dalile</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Van Oudenhove</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Vervliet</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Verbeke</surname><given-names>K.</given-names></name></person-group><article-title>The role of short-chain fatty acids in microbiota-gut-brain communication</article-title>. <source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2019</year>; <volume>16</volume>:<fpage>461</fpage>–<lpage>478</lpage>.<pub-id pub-id-type="pmid">31123355</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piwowarski</surname><given-names>J.P.</given-names></name>, <name name-style="western"><surname>Granica</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Stefanska</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Kiss</surname><given-names>A.K.</given-names></name></person-group><article-title>Differences in metabolism of ellagitannins by human gut microbiota ex vivo cultures</article-title>. <source>J. Nat. Prod.</source><year>2016</year>; <volume>79</volume>:<fpage>3022</fpage>–<lpage>3030</lpage>.<pub-id pub-id-type="pmid">28006907</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Claus</surname><given-names>S.P.</given-names></name>, <name name-style="western"><surname>Guillou</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Ellero-Simatos</surname><given-names>S.</given-names></name></person-group><article-title>The gut microbiota: a major player in the toxicity of environmental pollutants</article-title>. <source>NPJ Biofilms Microbiomes</source>. <year>2016</year>; <volume>2</volume>:<fpage>16003</fpage>.<pub-id pub-id-type="pmid">28721242</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>X.P.</given-names></name>, <name name-style="western"><surname>D'Souza</surname><given-names>A.W.</given-names></name>, <name name-style="western"><surname>Boolchandani</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>S.H.</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Luis Martinez</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>Y.J.</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>L.X.</given-names></name><etal>et al</etal>.</person-group><article-title>Environmental remodeling of human gut microbiota and antibiotic resistome in livestock farms</article-title>. <source>Nat. Commun.</source><year>2020</year>; <volume>11</volume>:<fpage>1427</fpage>.<pub-id pub-id-type="pmid">32188862</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Javurek</surname><given-names>A.B.</given-names></name>, <name name-style="western"><surname>Spollen</surname><given-names>W.G.</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>S.A.</given-names></name>, <name name-style="western"><surname>Bivens</surname><given-names>N.J.</given-names></name>, <name name-style="western"><surname>Bromert</surname><given-names>K.H.</given-names></name>, <name name-style="western"><surname>Givan</surname><given-names>S.A.</given-names></name>, <name name-style="western"><surname>Rosenfeld</surname><given-names>C.S.</given-names></name></person-group><article-title>Effects of exposure to bisphenol A and ethinyl estradiol on the gut microbiota of parents and their offspring in a rodent model</article-title>. <source>Gut Microbes</source>. <year>2016</year>; <volume>7</volume>:<fpage>471</fpage>–<lpage>485</lpage>.<pub-id pub-id-type="pmid">27624382</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baxter</surname><given-names>N.T.</given-names></name>, <name name-style="western"><surname>Zackular</surname><given-names>J.P.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>G.Y.</given-names></name>, <name name-style="western"><surname>Schloss</surname><given-names>P.D.</given-names></name></person-group><article-title>Structure of the gut microbiome following colonization with human feces determines colonic tumor burden</article-title>. <source>Microbiome</source>. <year>2014</year>; <volume>2</volume>:<fpage>20</fpage>.<pub-id pub-id-type="pmid">24967088</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weir</surname><given-names>T.L.</given-names></name>, <name name-style="western"><surname>Manter</surname><given-names>D.K.</given-names></name>, <name name-style="western"><surname>Sheflin</surname><given-names>A.M.</given-names></name>, <name name-style="western"><surname>Barnett</surname><given-names>B.A.</given-names></name>, <name name-style="western"><surname>Heuberger</surname><given-names>A.L.</given-names></name>, <name name-style="western"><surname>Ryan</surname><given-names>E.P.</given-names></name></person-group><article-title>Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults</article-title>. <source>PLoS One</source>. <year>2013</year>; <volume>8</volume>:<fpage>e70803</fpage>.<pub-id pub-id-type="pmid">23940645</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liddicoat</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Sydnor</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Cando-Dumancela</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Dresken</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Gellie</surname><given-names>N.J.C.</given-names></name>, <name name-style="western"><surname>Mills</surname><given-names>J.G.</given-names></name>, <name name-style="western"><surname>Young</surname><given-names>J.M.</given-names></name>, <name name-style="western"><surname>Weyrich</surname><given-names>L.S.</given-names></name>, <name name-style="western"><surname>Hutchinson</surname><given-names>M.R.</given-names></name><etal>et al</etal>.</person-group><article-title>Naturally-diverse airborne environmental microbial exposures modulate the gut microbiome and may provide anxiolytic benefits in mice</article-title>. <source>Sci. Total Environ.</source><year>2020</year>; <volume>701</volume>:<fpage>134684</fpage>.<pub-id pub-id-type="pmid">31704402</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schirmer</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Smeekens</surname><given-names>S.P.</given-names></name>, <name name-style="western"><surname>Vlamakis</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Jaeger</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Oosting</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Franzosa</surname><given-names>E.A.</given-names></name>, <name name-style="western"><surname>Ter Horst</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Jansen</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Jacobs</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Bonder</surname><given-names>M.J.</given-names></name><etal>et al</etal>.</person-group><article-title>Linking the human gut microbiome to inflammatory cytokine production capacity</article-title>. <source>Cell</source>. <year>2016</year>; <volume>167</volume>:<fpage>1125</fpage>–<lpage>1136</lpage>.<pub-id pub-id-type="pmid">27814509</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gehrig</surname><given-names>J.L.</given-names></name>, <name name-style="western"><surname>Venkatesh</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>H.W.</given-names></name>, <name name-style="western"><surname>Hibberd</surname><given-names>M.C.</given-names></name>, <name name-style="western"><surname>Kung</surname><given-names>V.L.</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>R.Y.</given-names></name>, <name name-style="western"><surname>Subramanian</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Cowardin</surname><given-names>C.A.</given-names></name>, <name name-style="western"><surname>Meier</surname><given-names>M.F.</given-names></name><etal>et al</etal>.</person-group><article-title>Effects of microbiota-directed foods in gnotobiotic animals and undernourished children</article-title>. <source>Science</source>. <year>2019</year>; <volume>365</volume>:<fpage>eaau4732</fpage>.<pub-id pub-id-type="pmid">31296738</pub-id></mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iida</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Dzutsev</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Stewart</surname><given-names>C.A.</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Bouladoux</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Weingarten</surname><given-names>R.A.</given-names></name>, <name name-style="western"><surname>Molina</surname><given-names>D.A.</given-names></name>, <name name-style="western"><surname>Salcedo</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Back</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Cramer</surname><given-names>S.</given-names></name><etal>et al</etal>.</person-group><article-title>Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment</article-title>. <source>Science</source>. <year>2013</year>; <volume>342</volume>:<fpage>967</fpage>–<lpage>970</lpage>.<pub-id pub-id-type="pmid">24264989</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendez</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Gaulton</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Bento</surname><given-names>A.P.</given-names></name>, <name name-style="western"><surname>Chambers</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>De Veij</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Felix</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Magarinos</surname><given-names>M.P.</given-names></name>, <name name-style="western"><surname>Mosquera</surname><given-names>J.F.</given-names></name>, <name name-style="western"><surname>Mutowo</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Nowotka</surname><given-names>M.</given-names></name><etal>et al</etal>.</person-group><article-title>ChEMBL: towards direct deposition of bioassay data</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D930</fpage>–<lpage>D940</lpage>.<pub-id pub-id-type="pmid">30398643</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Ren</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>Y.</given-names></name><etal>et al</etal>.</person-group><article-title>Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D1031</fpage>–<lpage>D1041</lpage>.<pub-id pub-id-type="pmid">31691823</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>He</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Qin</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Tao</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><etal>et al</etal>.</person-group><article-title>NPASS: natural product activity and species source database for natural product research, discovery and tool development</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D1217</fpage>–<lpage>D1222</lpage>.<pub-id pub-id-type="pmid">29106619</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Xue</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Qin</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>Y.</given-names></name><etal>et al</etal>.</person-group><article-title>1,520 reference genomes from cultivated human gut bacteria enable functional microbiome analyses</article-title>. <source>Nat. Biotechnol.</source><year>2019</year>; <volume>37</volume>:<fpage>179</fpage>–<lpage>185</lpage>.<pub-id pub-id-type="pmid">30718868</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levy</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Magis</surname><given-names>A.T.</given-names></name>, <name name-style="western"><surname>Earls</surname><given-names>J.C.</given-names></name>, <name name-style="western"><surname>Manor</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Wilmanski</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Lovejoy</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Gibbons</surname><given-names>S.M.</given-names></name>, <name name-style="western"><surname>Omenn</surname><given-names>G.S.</given-names></name>, <name name-style="western"><surname>Hood</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Price</surname><given-names>N.D.</given-names></name></person-group><article-title>Longitudinal analysis reveals transition barriers between dominant ecological states in the gut microbiome</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2020</year>; <volume>117</volume>:<fpage>13839</fpage>–<lpage>13845</lpage>.<pub-id pub-id-type="pmid">32471946</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Letunic</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Bork</surname><given-names>P.</given-names></name></person-group><article-title>Interactive Tree Of Life (iTOL) v4: recent updates and new developments</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>W256</fpage>–<lpage>W259</lpage>.<pub-id pub-id-type="pmid">30931475</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
